CY1109862T1 - Χρηση συνθεσεων που περιεχουν ανταγωνιστες των καππα υποδοχεων των οπιοειδων για τη θεραπεια διασχιστικων διαταραχων - Google Patents

Χρηση συνθεσεων που περιεχουν ανταγωνιστες των καππα υποδοχεων των οπιοειδων για τη θεραπεια διασχιστικων διαταραχων

Info

Publication number
CY1109862T1
CY1109862T1 CY20101100188T CY101100188T CY1109862T1 CY 1109862 T1 CY1109862 T1 CY 1109862T1 CY 20101100188 T CY20101100188 T CY 20101100188T CY 101100188 T CY101100188 T CY 101100188T CY 1109862 T1 CY1109862 T1 CY 1109862T1
Authority
CY
Cyprus
Prior art keywords
treatment
disorders
intermittent
opioid receptor
compositions containing
Prior art date
Application number
CY20101100188T
Other languages
Greek (el)
English (en)
Inventor
Lars-Holger Dr Hermann
Original Assignee
Emodys Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006015733A external-priority patent/DE102006015733A1/de
Priority claimed from DE102006016991A external-priority patent/DE102006016991A1/de
Application filed by Emodys Gmbh filed Critical Emodys Gmbh
Publication of CY1109862T1 publication Critical patent/CY1109862T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CY20101100188T 2006-04-04 2010-02-25 Χρηση συνθεσεων που περιεχουν ανταγωνιστες των καππα υποδοχεων των οπιοειδων για τη θεραπεια διασχιστικων διαταραχων CY1109862T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006015733A DE102006015733A1 (de) 2006-04-04 2006-04-04 Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit
DE102006016991A DE102006016991A1 (de) 2006-04-11 2006-04-11 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen
EP07727719A EP2001456B1 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Publications (1)

Publication Number Publication Date
CY1109862T1 true CY1109862T1 (el) 2014-09-10

Family

ID=38110094

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100188T CY1109862T1 (el) 2006-04-04 2010-02-25 Χρηση συνθεσεων που περιεχουν ανταγωνιστες των καππα υποδοχεων των οπιοειδων για τη θεραπεια διασχιστικων διαταραχων

Country Status (17)

Country Link
US (1) US8063059B2 (https=)
EP (1) EP2001456B1 (https=)
JP (1) JP5128578B2 (https=)
AT (1) ATE450256T1 (https=)
AU (1) AU2007236003B2 (https=)
CA (1) CA2646899C (https=)
CY (1) CY1109862T1 (https=)
DE (1) DE502007002185D1 (https=)
DK (1) DK2001456T3 (https=)
EA (1) EA014820B1 (https=)
ES (1) ES2337622T3 (https=)
HR (1) HRP20100113T1 (https=)
PL (1) PL2001456T3 (https=)
PT (1) PT2001456E (https=)
RS (1) RS51211B (https=)
SI (1) SI2001456T1 (https=)
WO (1) WO2007115975A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094260A1 (en) 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist
MX368870B (es) * 2013-12-20 2019-10-21 H Lundbeck As Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
PL3137081T3 (pl) 2014-04-28 2018-06-29 Orphomed, Inc. Dimer buprenorfiny i jego zastosowanie w leczeniu chorób układu pokarmowego
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
EP1061924A1 (en) * 1998-03-09 2000-12-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
US20020045572A1 (en) * 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
AU2001275959A1 (en) 2000-08-15 2002-02-25 Cpd Llc Method of treating the syndrome of type 2 diabetes in humans
JP2004518654A (ja) * 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
EP1613617A4 (en) * 2003-04-04 2009-02-18 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS
JP2007526328A (ja) * 2004-03-02 2007-09-13 ファルマシア コーポレーション 単独および抗うつ薬と組み合わせた形のCox−2阻害剤によって精神障害を治療または予防するための方法および組成物
WO2005117910A2 (en) * 2004-05-26 2005-12-15 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
ATE412404T1 (de) 2004-06-02 2008-11-15 Galephar M F Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon

Also Published As

Publication number Publication date
US20090181999A1 (en) 2009-07-16
EA200802104A1 (ru) 2009-04-28
WO2007115975A2 (de) 2007-10-18
DK2001456T3 (da) 2010-04-12
PL2001456T3 (pl) 2010-05-31
EP2001456B1 (de) 2009-12-02
AU2007236003B2 (en) 2012-10-18
AU2007236003A1 (en) 2007-10-18
JP5128578B2 (ja) 2013-01-23
HRP20100113T1 (hr) 2010-04-30
US8063059B2 (en) 2011-11-22
SI2001456T1 (sl) 2010-04-30
CA2646899C (en) 2014-05-06
EA014820B1 (ru) 2011-02-28
CA2646899A1 (en) 2007-10-18
RS51211B (sr) 2010-12-31
JP2009532434A (ja) 2009-09-10
ATE450256T1 (de) 2009-12-15
WO2007115975A3 (de) 2008-02-14
DE502007002185D1 (de) 2010-01-14
ES2337622T3 (es) 2010-04-27
EP2001456A2 (de) 2008-12-17
PT2001456E (pt) 2010-03-03

Similar Documents

Publication Publication Date Title
CY1109862T1 (el) Χρηση συνθεσεων που περιεχουν ανταγωνιστες των καππα υποδοχεων των οπιοειδων για τη θεραπεια διασχιστικων διαταραχων
CY1123549T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
EA201171403A1 (ru) Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
CY1117143T1 (el) Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
CY1117424T1 (el) Βενζοδιαζεπινικος αναστολεας bromodomain
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
CR10379A (es) Composiones farmaceuticas de antagonistas del anticuerpo anti-cd40.
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
NO20084531L (no) Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
EA200801997A1 (ru) Новые соединения
EA201171074A1 (ru) Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα